key: cord-0696966-f1nkiuoe authors: Li, Ling; Jin, Xiao‐jie; Li, Jia‐wei; Li, Cheng‐hao; Zhou, Shuang‐yan; Li, Jun‐jie; Feng, Cai‐qin; Liu, Dong‐ling; Liu, Yong‐qi title: Systematic insight into the active constituents and mechanism of Guiqi Baizhu for the treatment of gastric cancer date: 2021-03-07 journal: Cancer Sci DOI: 10.1111/cas.14851 sha: 6585d5845646db187ad2dd2ebed54dc27171e341 doc_id: 696966 cord_uid: f1nkiuoe Traditional Chinese medicine treatment of diseases has been recognized, but the material basis and mechanisms are not clear. In this study, target prediction of the antigastric cancer (GC) effect of Guiqi Baizhu (GQBZP) and the analysis of potential key compounds, key targets, and key pathways for the therapeutic effects against GC were carried out based on the method of network analysis and Kyoto Encyclopedia of Genes and Genomes enrichment. There were 33 proteins shared between GQBZP and GC, and 131 compounds of GQBZP had a high correlation with these proteins, indicating that the PI3K‐AKT signaling pathway might play a key role in GC. From these studies, we selected human epidermal growth factor receptor 2 (HER2) and programmed cell death 1‐ligand 1 (PD‐L1) for docking; the results showed that 385 and 189 compounds had high docking scores with HER2 and PD‐L1, respectively. Six compounds were selected for microscale thermophoresis (MST). Daidzein/quercetin and isorhamnetin/formononetin had the highest binding affinity for HER2 and PD‐L1, with K (d) values of 3.7 μmol/L and 490, 667, and 355 nmol/L, respectively. Molecular dynamics simulation studies based on the docking complex structures as the initial conformation yielded the binding free energy between daidzein/quercetin with HER2 and isorhamnetin/formononetin with PD‐L1, calculated by molecular mechanics Poisson‐Boltzmann surface area, of −26.55, −14.18, −19.41, and −11.86 kcal/mol, respectively, and were consistent with the MST results. In vitro experiments showed that quercetin, daidzein, and isorhamnetin had potential antiproliferative effects in MKN‐45 cells. Enzyme activity assays showed that quercetin could inhibit the activity of HER2 with an IC(50) of 570.07 nmol/L. Our study provides a systematic investigation to explain the material basis and molecular mechanism of traditional Chinese medicine in treating diseases. Gastric cancer is one of the most common malignant tumors in the world. 1 Due to the high heterogeneity of GC, it is a disease involving multiple genes and multiple targets, making treatment difficult. 2 Therefore, it is urgent to explore new treatment methods. Blockers targeting PD-L1, 3 PD-1, 4 HER2, 5 and other targets have become an important direction in study of GC. Overexpression of HER2 in GC patients is often positively correlated with PD-L1 expression, which could depend on the PI3K-AKT-mTOR pathway, 6 suggesting that the combination of drugs aimed at the above targets might be a new therapeutic pathway. The multipoint fine adjustment, coordination, and efficacy enhancement effect of TCM have the characteristics of supporting the healthy factors and eliminating pathogenic factors, which should be advantageous in antitumor treatment. However, the current pharmacological evaluation method of TCM is still based on a single "disease gene-target drug" research model. 7 The specific mechanism for effects of many TCM formulas on cancer still needs further investigation, given that the chemical composition of TCM is very complex. The further evaluation of the pharmacodynamic function of TCM compounds and to determine their mechanisms of action are the focus of further research. Guiqi Baizhu prescription is modified from Huang Qi prescription in volume 272 of "Prescriptions for Universal Relief". 8 Previous experiments showed that GQBZP could reduce liver 9 and kidney 10 functional damage induced by cisplatin, can improve the quality of life for patients with GC during chemotherapy, and regulate the immune balance. 11 However, the molecular mechanism and material basis of its effectiveness remain unclear. Molecular docking and network pharmacology are widely used to study the material basis and mechanism of TCM in the prevention and treatment of disease. [12] [13] [14] Network pharmacology provides a new approach to systematically search for the active components and targets of TCM. Network pharmacology fits the multicomponent, multitarget dynamics of TCM and helps to identify the molecular mechanism of the overall effects of TCM. 15 Computer-aided drug design, such as molecular docking and molecular dynamics simulations, is used to calculate the interaction and affinity between a compound and a target to generate the material basis and mechanism of action of TCM by virtual screening. 16, 17 For protein-ligand binding interactions, the MM-PBSA method is usually applied to the calculation of binding free energies (ΔG bind ) of small molecule ligands bound to large biomolecule receptors. 18 Microscale thermophoresis is used to determine the affinity of the interacting biomolecules with high sensitivity. 19 Microscale thermophoresis can be used to identify appropriate compounds for cell experiments. In this study, we identify key targets and potentially active compounds using network pharmacology, molecular docking, and MM-PBSA calculation. We used cell research, MST, and enzyme activity analysis to verify the activity of selected compounds and thereby identify and characterize the material basis and mechanism of GQBZP in the treatment of GC. The drug targets for "GC" were retrieved by using "gastric cancer" and "gastric carcinoma" as keywords through TTD 23 and Drug Bank. 24 The common targets of GQBZP and GC were obtained by intersection. Based on the identified anti-GC targets of GQBZP, a herbscompounds-targets network was constructed in Cytoscape 3.6.2, 25 and the degree value of compounds in the network was used to analyze the principal effective compounds of herbs. to explain the material basis and molecular mechanism of traditional Chinese medicine in treating diseases. gastric cancer, Guiqi Baizhu prescription, molecular docking, molecular dynamics simulation, MST analysis, network pharmacology 2.1.4 | Kyoto Encyclopedia of Genes and Genomes enrichment and PPI analysis The anti-GC targets of GQBZP were imported into DAVID. 26 The Select identifier was the official gene symbol, the List type was the gene list, the limited species was Homo sapiens, the threshold was P <.05, and KEGG pathway analysis was carried out. The online analysis platform Omicshare was used to visualize the enrichment path. 27 String 28 was used to analyze the PPI of the target, the species selected was Homo sapiens, and the comprehensive score for protein interaction was set as greater than 0.7 as the screening condition. Finally, the PPI information was imported into Cytoscape 3.6.2 for network analysis. Through collection of compounds in GQBZP, a compound database of molecular docking was established. Drug-likeness was determined by Lipinski's rule. 29 The 3D structure of HER2 (PDB ID: 3RCD) 30 and PD-L1(PDB ID: 4Z18) 31 were downloaded from PDB databases. 32 The binding pocket of HER2 was the substrate-binding site and the active residues of HER2 were Lys753, Asp863, Thr862, Phe864, and Met801. 30 The PD-L1 binding pocket belonged to protein-protein interface binding sites and the potential active residues were Tyr56, Met115, Ala121, Tyr123, and Asp122. 31 Finally, the Prep Wiz module was used to preprocess these targets in Schrödinger. The screen greedy box center read of HER2 was x cent −38.142190, y cent −29.102648, and z cent −74.036287, with the size of the box at 10 Å. The screen greedy box center read of PD-L1 was x cent −6.006301, y cent −15.078195, and z cent −4.842327, with the size of the box at 10 Å. With a confidence of 68%, the K d value is within the given range. The initial structure of the proteins complex with compounds was obtained from molecular docking. Structure optimization and frequency calculations for the small molecule quercetin, daidzein, isorhamnetin, and formononetin were determined at the HF/6-31G* level of Gaussian 09. The restrained electrostatic potential was used to describe the partial atomic charges. The parameters for the small molecules were generated from Amber force field. 38 The standard Amber force field for bioorganic systems 39 was used to describe the protein. The counter ions were added to neutralize each system. All systems were solvated using an atomistic TIP3P 39 water box with at least 10 Å distance around the complex. Following this step, another two rounds of energy minimization were undertaken by restraining only protein and further releasing all the restraints for 5000 steps of each round. Long-range Coulombic interactions were handled using the particle mesh Ewald (PME) summation. 39 For the equilibration and subsequent production runs, the SHAKE algorithm 41 was used on all atoms covalently bonded to a hydrogen atom, allowing for an integration time step of 2 fs. The systems were gently annealed from 0 to 310 K over a period of 50 ps using a Langevin thermostat with a coupling coefficient of 1.0/ps and a force constant 2.0 kcal/mol·Å 2 on the complex. All subsequent stages were carried out in the isothermal isobaric (NPT) ensemble using a Berendsen barostat with a target pressure of 1 bar. An additional five rounds of MD (100 ps each at 310 K) were carried out with decreasing restraint weights from 2.0, 1.5, 1.0, 0.5 to 0.1 kcal/ mol·Å 2 . By releasing all the restrains, the system was again equilibrated for 500 ps. The production phase of the simulations was run without any restrains for a total of 50 ns. The MM-PBSA calculation was carried out using Amber20. 42 The first step of the MM-PBSA method is the generation of multiple snapshots from a molecular dynamics trajectory of the protein-ligand complex, which was stripped of water molecules and counter ions. Two hundred and fifty snapshots, equally spaced at 20 ps intervals, were extracted from the equilibration section (last 10 ns) of the molecular dynamics trajectory. For each snapshot, the free energy was calculated for each molecular species (complex, protein, and ligand). The binding free energy was computed as the difference 42 : All enzymatic reactions were carried out at 30°C for 40 min. The Membranes were incubated with secondary Abs followed by enhanced chemiluminescence reagents (Yeasen). The GAPDH protein was used as a reference. 43 The GC cells were incubated with HER2 Ab (1:250) or PD-L1 (1:200) diluted in PBS containing 1% BSA and incubated overnight at 4°C, followed by addition of fluorescentlabeled secondary Abs (Alexa Fluor 647; Abcam) for 1 h at room temperature. 44 MKN-45 cells with approximately 6 × 10 3 cells/well were plated in a 96-well standard microplate in DMEM with 10% FBS, 1% penicillin, and 1% streptomycin, and incubated in 5% CO 2 . After the cells became adherent, the medium was replaced and different doses of compounds were added. Cells were exposed to various concentrations (five serial dilutions in triplicate) of quercetin, daidzein, isorhamnetin, and formononetin. After 72 h of culture, the medium was removed and 100 µl DMEM, supplemented with 10% CCK-8, was added to each well and incubated in the dark for an additional 2 h at 37°C. The absorbance was then measured using microplate reader (iMark; Bio-Rad) at a wavelength of 450 nm. The cell viability was expressed as a percentage of the control values (blank). The experiments were done in triplicate. Differences among three or more experimental samples were analyzed by ANOVA. Significance was set at P <.05. The seven herbs in GQBZP all belong to the spleen meridian, which has the characteristics of both attacking and supplementing by strengthening the spleen and stimulating blood flow. Information on each herb is shown in Table 1 . In this study, 787 compounds were collected, which were mainly flavonoids, alkaloids, and coumarins. Their structures are shown in Figures S1-S61. The potential targets of the seven herbs of GQBZP were predicted by the Swiss Target Prediction database, and 885 targets were obtained after removing duplicates. One hundred and twenty nine GC potential targets were obtained from the Drug Bank and TTD database after removing duplicates, and 33 key potential targets were finally ob- (52), (48), TOP1 (37), ODC1 (34) , and AKT1 (29) are the potential key targets of GQBZP ( Table 2 ). The PPI network ( Figure 1B In this study, 787 compounds were collected, 483 of which conformed to Lipinski's rule ( Table 3 ). The structure of HER2 and PD-L1 proteins are shown in Figure 2 . After docking, scores were obtained and expressed in absolute values, and the small molecules with high scores in different herbs are shown in Table 3 . The results show that 385 compounds having drug-like properties in GQBZP had a docking score of −4 or lower with HER2, and 189 had a docking score of −4 or lower with PD-L1. Table 4 and Table 5 list the small molecules with higher scores after docking with the target proteins. The docking results show that Astragali radix, Angelicae, and rhubarb in GQBZP contained potential active ingredients, which corresponds with the effects of Astragali radix in prescriptions on invigorating qi and the spleen, Angelicae in nourishing blood and replenishing blood, and rhubarb in promoting blood circulation. From the two-way effect of regulating immunity and treating tumors, it preliminarily explains that GQBZP might play a coordinated role in the treatment of GC through multiple targets, such as HER2 and PD-L1. 50 Six compounds that targeted HER2 and PD-L1 were selected for MST experiments after docking. More than 12 concentration gradients were used to fit the K d value of the equilibrium dissociation con- Although Our cell experiments yielded different results, however, which warrants further exploration. According to the molecular docking analysis and cell proliferation assays, target prediction suggested that quercetin might be a potential HER2 kinase inhibitor. To verify this and explore the mechanisms of the compounds, the inhibitory effects of quercetin against the HER2 kinase were determined. The results show that quercetin strongly suppresses HER2 kinases, with an IC 50 value of 570.07 nmol/L, as shown in Figure 7 . The therapeutic effect of compounds of TCM might not be better than that of mAbs, but they have the advantages of high oral bioavailability and few side-effects, and so have great prospects for clinical development. Quercetin and formononetin in GQBZP have stronger affinity for HER2 and PD-L1, respectively, and could be the key compounds in the prescriptions for two-way treatment of cancer by inhibiting the proliferation of cancer cells and improving the immune function of the body. Traditional Chinese medicine is a comprehensive medicinal system, which has potential utilization based on thousands of years in clinical practice in China, providing the characteristics of multicomponents and multitargets and presenting a potent synergistic effect for treatment of various diseases with fewer side-effects. 67 The effectiveness of TCM in treating diseases has been recognized worldwide, 68 The authors have no conflict of interest. https://orcid.org/0000-0002-9349-8332 Next generation sequencing-based emerging trends in molecular biology of gastric cancer Genomic and epigenomic heterogeneity in molecular subtypes of gastric cancer Avelumab in gastric cancer Pathological complete response after a single dose of Anti-PD-1 therapy in combination with chemotherapy as a first-line setting in an unresectable locally advanced gastric cancer with PD-L1 positive and microsatellite instability Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion Network pharmacology: the next paradigm in drug discovery Beijing: People's Health Publishing House Protective effect of GuiQi Baizhu Recipe on hepatotoxicity induced by cisplatin in mice Attenuation effect of Guiqi Baizhu prescription on renal injury induced by cisplatin Clinical trial of the auxiliary treatment with Gui Qi Bai Zhu fang in the treatment of patients with gastric cancer System bioinformatic approach through molecular docking, network pharmacology and microarray data analysis to determine the molecular mechanism underlying the effects of rehmanniae Radix praeparata on cardiovascular diseases Network pharmacology and molecular docking analysis on molecular targets and mechanisms of Huashi Baidu formula in the treatment of COVID-19 A systems biology-based approach to uncovering molecular mechanisms underlying effects of traditional Chinese medicine Qingdai in chronic myelogenous leukemia, involving integration of network pharmacology and molecular docking technology Integrating network pharmacology and pharmacological evaluation for deciphering the action mechanism of herbal formula Zuojin Pill in suppressing hepatocellular carcinoma Exploring the mechanism of Danshen against Myelofibrosis by network pharmacology and molecular docking Challenges, applications, and recent advances of protein-ligand docking in structure-based drug design Recent developments and applications of the MMPBSA method Microscale thermophoresis quantifies biomolecular interactions under previously challenging conditions TCMSP: a database of systems pharmacology for drug discovery from herbal medicines PubChem 2019 update: improved access to chemical data SwissTargetPrediction: a web server for target prediction of bioactive small molecules Therapeutic target database DrugBank 5.0: a major update to the DrugBank database for 2018 Cytoscape Web: an interactive web-based network browser Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources Competing endogenous RNA (ceRNA) hypothetic model based on comprehensive analysis of long non-coding RNA expression in lung adenocarcinoma STRING v9.1: proteinprotein interaction networks, with increased coverage and integration Oral administration of peptidebased drugs: beyond Lipinski's Rule Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold Structure of the complex of human programmed death 1, PD-1, and its ligand PD-L1 The protein data bank Structural studies on inhibitory mechanisms of antibiotic, corticosteroid and catecholamine molecules on lactoperoxidase Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy Evaluation of pKa estimation methods on 211 druglike compounds PyMOL and inkscape bridge the data and the data visualization Development and testing of a general amber force field Staggered mesh Ewald: an extension of the smooth particle-mesh Ewald method adding great versatility Alchemical binding free energy calculations in Amber20: advances and best practices for drug discovery Molecular dynamics simulation with weak coupling to heat and material baths Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models Heat shock protein 22 attenuates doxorubicin-induced cardiotoxicity via regulating inflammation and apoptosis Ferulin C triggers potent PAK1 and p21-mediated anti-tumor effects in breast cancer by inhibiting Tubulin polymerization in vitro and in vivo MUC4-ErbB2 oncogenic complex: binding studies using microscale thermophoresis Cell autonomous or systemic EGFR blockade alters the immune-environment in squamous cell carcinomas EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release Immunotherapy combined or sequenced with targeted therapy in the treatment of solid tumors: current perspectives Trial watch: the clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors Study of collaborative evaluation system on synergistic pharmacological effect of chinese formula with multicomponents and multi-targets Targeting EGFR/ HER2 tyrosine kinases with a new potent series of 6-substituted 4-anilinoquinazoline hybrids: Design, synthesis, kinase assay, cellbased assay, and molecular docking Discovery of a potential HER2 inhibitor from natural products for the treatment of HER2-positive breast cancer Bioactive macrocyclic inhibitors of the PD-1/PD-L1 immune checkpoint Structural biology of the immune checkpoint receptor PD-1 and its ligands PD-L1/PD-L2 Antitumor activity of the PD-1/PD-L1 binding inhibitor BMS-202 in the humanized MHCdouble knockout NOG mouse Immunomodulatory effects of Hedysarum polybotrys extract in mice macrophages, splenocytes and leucopenia Formononetin, a phyto-oestrogen, and its metabolites up-regulate interleukin-4 production in activated T cells via increased AP-1 DNA binding activity Effect of the Miaoyao Fanggan sachet-derived isorhamnetin on TLR2/4 and NKp46 expression in mice Isorhamnetin, the active constituent of a Chinese herb Hippophae rhamnoides L, is a potent suppressor of dendritic-cell maturation and trafficking Systematic exploration of Astragalus membranaceus and Panax ginseng as immune regulators: Insights from the comparative biological and computational analysis Anticancer potential of quercetin: a comprehensive review Differential effects of flavonoid compounds on tumor promoter-induced activation of the human CYP1A2 enhancer Multitargeted cancer prevention by quercetin Quercetin in cancer treatment, alone or in combination with conventional therapeutics Recent advances in small molecule based cancer immunotherapy Research progress in the modification of quercetin leading to anticancer agents The multi-target capabilities of the compounds in a TCM used to treat sepsis and their in silico pharmacology Exploring Chinese medicine and Western medicine group modules in acute phase of ischemic stroke disease Molecular mechanism and research progress on pharmacology of traditional Chinese medicine in liver injury The therapeutical effect of Chinese medicine for the treatment of atherosclerotic coronary heart disease Systematic insight into the active constituents and mechanism of Guiqi Baizhu for the treatment of gastric cancer